The company has also launched the UV 400 Viraguard, which uses high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber to trap and destroy harmful microbes.
The device draws air in through a killing chamber cartridge where baffles provide the turbulence necessary to bring microbes in close proximity to the special UVC lamps, allowing the germicidal UV-C to kill any pathogens present. Before exiting, the air stream passes through a gross particulate screen, which removes the neutralised dust and debris. The sealed cartridge can be discarded with regular waste after 12 months of continuous operation.
Independent testing by EPA and US FDA certified laboratories has confirmed that the system captures and kills many airborne bacteria and viruses including Influenza A and H1N1 at rates exceeding 99.2%, the company says. The FDA has issued a Class II medical listing that enables UV Flu Technologies to market the UV 400 Viraguard as a medical device.
As a result, UV Flu Technologies says it is ramping up production towards servicing sales into the early adopter target market sector, which includes hospitals, doctors’ waiting rooms and institutions. Future sales efforts are anticipated to broaden the scope to include a range of public facilities and consumer interests.
The US IAQ market generated more than US$7.7bn in 2008, with the equipment segment accounting for US$3.6bn. Early year-end results for 2009 show continued strength across the sector, the company says.
Contact www.uvflutech.com